Start Your Search
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Presentations: 2
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
P006 - Evaluation of Efficacy and Safety of Uniportal Segmentectomy in the Treatment of Small Lung Nodule (ID 125)
00:00 - 00:00 | Author(s): H. Liu
Uniportal segmentectomy is a therapeutic option for small lung nodule, but the debate over uniportal segmentectomy still remains. The aim of this study is to evaluate of efficacy and safety of uniportal segmentectomy in the treatment of small lung nodule.
A total of 85 patients who underwent uniportal segmentectomy or subsegmentectomy between January 2017 and September 2018 in Liaoning Cancer Hospital. The clinical data of these patients were retrospectively analyzed, including operation time, number of lymph nodes dissected and postoperative mortality, postoperative complications, postoperative intubation time, and postoperative hospital stay.
The surgery procedure was anatomical pulmonary segmentectomy or subsegmentectomy. Uniportal segmentectomy was in 81 cases, and subsegmentectomy was in 4 cases. The median operation time was 243 minutes (range, 60-405 minutes), median number of lymph nodes dissected was 14 (range, 0-31), median postoperative intubation time was 5 days (range, 1-9 days), median postoperative hospital stay was 8 days (range, 3-19 days). The postoperative complications were pneumonia 1 case (1.2%), fever 9 cases (10.6%), hemoptysis 1 case (1.2%), air leak 1 case (1.2%), atrial fibrillation 1 case (1.2%), and subcutaneous hydrops 2 cases (2.4%). There was no severe postoperative complications, including death, bleeding, reoperation, and bronchopleural fistula.
Uniportal segmentectomy is a safe and feasible technique for treating small pulmonary lesions, with acceptable postoperative complications and mortality.
P024 - Sleeve Lobectomy for Centrally Located Non-Small Cell Lung Cancer: Experience of a Single Institute (ID 111)
00:00 - 00:00 | Author(s): H. Liu
To evaluate the feasibility and safety of sleeve lobectomy for centrally located non-small cell lung cancer and summarize our surgical experience.
Clinical data of 45 patients who underwent sleeve lobectomy at Department of Thoracic Surgery of Liaoning Cancer Hospital & Institute from November 2016 to June 2018 including 6 cases had neoadjuvant chemotherapy were collected retrospectively, and operative strategies, time of postoperative drainage, postoperative hospital stay and postoperative complications were also recorded.
All patients received sleeve lobectomy successfully. Of all the patients, 8 patients underwent bronchial and arterial sleeve lobectomy, 4 underwent bronchial sleeve resection and partial side wall of arterial resection, 2 underwent arterial sleeve resection and partial side wall of bronchial resection, 31 underwent bronchial sleeve resection only. There was no perioperative death in all patients. Margin status was R0 in 39 patients (86.7%), R1 in 5 patients (11.1%), R2 in 1 patient (2.2%). The median time of postoperative drainage was 7 days (3-26 days), median time of postoperative hospital stay was 11 days (6-28 days). Major complications occurred in 11 patients (24.4%), including 1 chylothorax, 6 pneumonia, 3 pleural effusion, 1 air leak. Endotracheal endoscopic sputum aspiration was performed in 11 patients postoperatively. Pathologic diagnosis showed squamous cell carcinoma in 35 patients, adenocarcinoma in 6 patients, adenosquamous carcinoma in 2 patients, and large cell carcinoma in 1 patient. 2 patients were in stage ?A3, 7 patients were in stage ?B, 2 patients were in stage ?A, 24 patients were in stage ?B, 5 patients were in stage ?A?and 4 patients were in stage ?B. All patients recovered well and were discharged uneventfully.
Sleeve lobectomy is a safe and feasible procedure for treatment of centrally located non-small-cell lung cancer. It is an accepted procedure to expand operation indications and avoid pneumonectomy, improve postoperative quality of life.